Menlo Park, California-based Phathom Pharmaceuticals, a newly launched biopharmaceutical company focused on treating gastrointestinal diseases and disorders, has secured $90 million in funding. Frazier Healthcare Partners led the round with participation from other investors that included Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen. Also, Phathom has secured a $50 million term loan facility from Silicon Valley Bank.
CAMBRIDGE, Mass. & MENLO PARK, Calif.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Frazier Healthcare Partners (“Frazier”) today announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Takeda has granted a license to Phathom for the development and exclusive commercialization rights to vonoprazan in the United States, Europe and Canada in exchange for upfront cash and equity, as well as future cash milestones and royalties on net sales. In connection with the license, Phathom has completed a $90 million crossover financing and $50 million debt facility.
Vonoprazan is a novel, orally active potassium competitive acid blocker (P-CAB) discovered and developed by Takeda. Takeda and Otsuka will continue to co-promote vonoprazan in Japan which they have done since 2015. Takeda will continue to market vonoprazan in several Asian markets where it is currently launched (Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand). P-CABs are a class of drug that competitively block the potassium-binding site of gastric hydrogen potassium ATPase (also known as the proton pump), which is the enzyme primarily responsible for acidification of the stomach.
“Takeda embraces collaboration to further develop and create value around promising assets where partnership makes more sense for our business,” said Asit Parikh, M.D., Ph.D., Head, Gastroenterology Therapeutic Area Unit at Takeda. “Phathom’s skilled leadership, with deep expertise in acid-related disorders, positions them well to expand access to vonoprazan in North America and Europe while Takeda continues to leverage its presence in Japan and several Asian markets.”
Following a standard eight-week course of proton pump inhibitor (PPI) therapy, 30–40 percent of patients with gastroesophageal reflux disease (GERD) continue to experience symptoms.1 PPIs in combination with antibiotics are also used for the eradication of H. pylori, which is associated with peptic ulcer disease and gastric cancer. However, the eradication rate of standard PPI-based triple therapy is reported to be 70-80%.2,3
“We are excited to have the opportunity to develop vonoprazan for the United States, Europe and Canada to address this immense unmet need,” said Tachi Yamada, M.D., Chairman of Phathom and Venture Partner with Frazier. “Phathom represents a truly unique opportunity to launch a new company around a highly experienced, world-class team developing a late-stage product candidate supported by strong clinical data and commercial experience.”
Phathom has completed a $90 million private financing led by Frazier Healthcare Partners with investments from Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation, Sahsen Ventures and undisclosed institutional investors. The company also completed a $50 million term loan facility with Silicon Valley Bank.
“We are very pleased with the quality of the investor group participating in this oversubscribed crossover financing,” said David Socks, interim Chief Executive Officer of Phathom and Venture Partner with Frazier. “We welcome their support in our efforts to advance vonoprazan, a next generation therapeutic with the potential to make a profound impact on the lives of patients with acid-related gastrointestinal disorders.”
Joining Tachi Yamada and David Socks on the Phathom board of directors are James Topper, M.D., Ph.D., Managing General Partner of Frazier Healthcare Partners, and Jon Edwards, Ph.D., Partner of Medicxi.
Takeda’s Commitment to Gastroenterology
Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.2 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information about Frazier Healthcare Partners, visit the company’s website at www.frazierhealthcare.com.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. For more information about Phathom, visit the company’s website at www.phathompharma.com.